600557.SH
康缘药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 11.91
−1.24%Year over year
Reported trailing growth
- Revenue
- -5.0%
- EBITDA
- —
- EBIT
- +11.8%
- EPS
- -11.0%
- Free cash flow
- —
- Operating cash flow
- +2.0%
Forward estimates
Based on analyst estimates
- Revenue
- -74.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.9%
- EBITDA
- -4.3%
- EBIT
- -6.6%
- Net income
- -11.2%
- EPS
- -10.4%
- Free cash flow
- -51.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026